Showing results (1411-1420 of 1,513) with videos related to
Sort By:
Pageof 152
Lancet (London, England)|May 27, 2014
London 2012 Olympic and Paralympic Games: public health surveillance and epidemiologyBrian McCloskey, Tina Endericks, Mike Catchpole, et al.Disaster Medicine and Public Health Preparedness|November 14, 2025
European Approach for Acute Radiation Syndrome's Management Facing Radiological and Nuclear Threats: A Call for ArmsMarc Benderitter, Pierre Arnautou, Cornelius Bartels, et al.Journal of Medicinal Chemistry|February 15, 2001
Discovery of 1-[3-(aminomethyl)phenyl]-N-3-fluoro-2'-(methylsulfonyl)-[1,1'-biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC423), a highly potent, selective, and orally bioavailable inhibitor of blood coagulation factor XaD J Pinto, M J Orwat, S Wang, et al.Immunity|December 18, 2014
Distinct epigenetic signatures delineate transcriptional programs during virus-specific CD8(+) T cell differentiationBrendan E Russ, Moshe Olshanksy, Heather S Smallwood, et al.Bioorganic & Medicinal Chemistry Letters|June 6, 2009
Design and synthesis of orally bioavailable serum and glucocorticoid-regulated kinase 1 (SGK1) inhibitorsMarlys Hammond, David G Washburn, H Tram Hoang, et al.Neuro-Oncology|April 16, 2013
Treating brain tumor-initiating cells using a combination of myxoma virus and rapamycinFranz J Zemp, Xueqing Lun, Brienne A McKenzie, et al.Bioorganic & Medicinal Chemistry Letters|September 12, 2006
Discovery of potent, efficacious, and orally bioavailable inhibitors of blood coagulation factor Xa with neutral P1 moietiesDonald J P Pinto, Robert A Galemmo, Mimi L Quan, et al.The European Respiratory Journal|May 8, 2024
European Respiratory Society clinical practice guideline on symptom management for adults with serious respiratory illnessAnne E Holland, Anna Spathis, Kristoffer Marsaa, et al.Journal of Medicinal Chemistry|December 4, 2003
Discovery of 1-(2-aminomethylphenyl)-3-trifluoromethyl-N- [3-fluoro-2'-(aminosulfonyl)[1,1'-biphenyl)]-4-yl]-1H-pyrazole-5-carboxyamide (DPC602), a potent, selective, and orally bioavailable factor Xa inhibitor(1)James R Pruitt, Donald J P Pinto, Robert A Galemmo, et al.Journal of Medicinal Chemistry|November 15, 2002
Synthesis and evaluation of indenopyrazoles as cyclin-dependent kinase inhibitors. 3. Structure activity relationships at C3(1,2)Eddy W Yue, C Anne Higley, Susan V DiMeo, et al.Pageof 152